Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 01:32 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with shares closing 177% higher, representing a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 01:27 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved recurrence-free survival when combined with Keytruda, leading to a 177% stock surge. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 01:22 PM UTC

Segments 13-17 describe Moderna's successful Phase 3 trial for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda, and a 177% stock surge. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 01:17 PM UTC

Segments 12-15 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 01:12 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a significant positive catalyst that led to a 177% stock surge, indicating improved expected fundamentals.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 01:07 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing longer recurrence-free survival when combined with Keytruda, and shares surged 177%, a clear positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 01:02 PM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer vaccine, showing improved recurrence-free survival compared to Keytruda alone. This is a significant positive catalyst for Moderna, supporting a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 12:57 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for the company, supporting a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 12:52 PM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a strong positive catalyst.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 12:47 PM UTC

Segments 13-17 describe Moderna's successful Phase 3 cancer vaccine trial, which led to a 177% increase in share price. This is a material positive catalyst for Moderna.